Clinical Trials
18 trialsNCT05768139 2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT06630325 2026-04-28
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT07145827 2025-09-12
Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen
Uruk University
Phase NA Completed
NCT05156892 2025-05-15
TICTOC
St Vincent's Hospital, Sydney
Phase 1 Active not recruiting
NCT02228681 2024-09-19
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT02584465 2023-09-06
REGOVAR
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT05669768 2023-01-03
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Sun Yat-sen University
Phase 2 Unknown
NCT00041080 2019-07-30
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00729586 2019-07-23
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01685255 2019-03-11
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Incyte Corporation
Phase 2 Terminated
NCT02728622 2016-04-05
Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Completed
NCT02482740 2015-06-26
TGOG1005
Buddhist Tzu Chi General Hospital
Phase 2 Unknown
NCT00305838 2013-08-12
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00016341 2013-04-11
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
GOG Foundation
Phase 3 Terminated
NCT00002920 2012-10-31
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00253539 2011-04-13
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00003080 2010-09-15
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00189358 2010-07-20
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
AGO Study Group
Phase 2 Completed